Jennison Associates LLC Has $43.44 Million Holdings in Adaptive Biotechnologies Corporation $ADPT

Key Points

• Jennison Associates LLC boosted its stake in Adaptive Biotechnologies by 103.9% in Q4, buying 1,363,181 shares to hold 2,674,668 shares worth about $43.44 million (≈1.75% of the company).
• Analysts have a consensus rating of Moderate Buy with an average price target of $19.43, and several firms (JPMorgan, BTIG) recently raised targets to $21–$22.
• Insiders sold a total of 2,587,099 shares (roughly $37.3 million) over the last three months — including CEO and COO sales executed under pre-arranged Rule 10b5‑1 plans — while insiders still own about 6.4% of the stock.

Jennison Associates LLC boosted its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report) by 103.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,674,668 shares of the company's stock after purchasing an additional 1,363,181 shares during the quarter. Jennison Associates LLC owned 1.75% of Adaptive Biotechnologies worth $43,437,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Assetmark Inc. raised its stake in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock valued at $49,000 after purchasing an additional 2,708 shares during the last quarter. Smartleaf Asset Management LLC raised its stake in Adaptive Biotechnologies by 593.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 3,939 shares of the company's stock valued at $59,000 after purchasing an additional 3,371 shares during the last quarter. Caxton Associates LLP acquired a new position in Adaptive Biotechnologies during the 1st quarter valued at $93,000. Mirae Asset Global Investments Co. Ltd. raised its stake in Adaptive Biotechnologies by 26.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company's stock valued at $120,000 after purchasing an additional 1,532 shares during the last quarter. Finally, Quadrant Capital Group LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter valued at $133,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ADPT shares. JPMorgan Chase & Co. upped their target price on shares of Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research note on Friday, February 6th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research note on Monday, April 20th. Wall Street Zen cut shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a research note on Saturday, March 7th. BTIG Research upped their target price on shares of Adaptive Biotechnologies from $21.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, February 6th. Finally, Piper Sandler set a $21.00 price target on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, Adaptive Biotechnologies presently has an average rating of "Moderate Buy" and a consensus price target of $19.43.

Adaptive Biotechnologies Price Performance

Shares of Adaptive Biotechnologies stock opened at $14.27 on Friday. The firm has a market capitalization of $2.28 billion, a PE ratio of -35.67 and a beta of 2.29. The company's fifty day moving average price is $14.35 and its two-hundred day moving average price is $15.94. Adaptive Biotechnologies Corporation has a 52-week low of $8.38 and a 52-week high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last announced its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. The firm had revenue of $71.68 million for the quarter, compared to analyst estimates of $59.38 million. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business's revenue for the quarter was up 51.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.23) EPS. Analysts predict that Adaptive Biotechnologies Corporation will post -0.5 earnings per share for the current fiscal year.

Insider Buying and Selling at Adaptive Biotechnologies

In other news, COO Julie Rubinstein sold 19,037 shares of the company's stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $14.23, for a total value of $270,896.51. Following the sale, the chief operating officer owned 377,802 shares of the company's stock, valued at approximately $5,376,122.46. This represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Chad M. Robins sold 37,263 shares of the company's stock in a transaction dated Wednesday, April 8th. The stock was sold at an average price of $15.19, for a total transaction of $566,024.97. Following the completion of the sale, the chief executive officer directly owned 2,180,518 shares in the company, valued at approximately $33,122,068.42. The trade was a 1.68% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 2,587,099 shares of company stock worth $37,296,664 in the last three months. Insiders own 6.40% of the company's stock.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

Want to see what other hedge funds are holding ADPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.